26 completed, 24 recruiting, 11 unknown, 7 not yet recruiting. 19 Phase 2, 13 Phase 3, 9 Not applicable, 8 Phase 4, 2 Phase 1.
Follow Nephrosis, Lipoid: new trials by email Literature Review of Nephrosis, Lipoid trials Research Report on Nephrosis, Lipoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-22 |
| A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD) Obinutuzumab Injection, Predniso(lo)ne - Minimal Change Disease (MCD) | Phase 2 | Recruiting | Medical University Innsbruck | 48 | 2026-07-13 | 2026-08-17 |
| Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome. Human Albumin 20%, Fresh Frozen Plasma - Idiopathic Nephrotic Syndrome (INS) | Not applicable | Not yet recruiting | Qamar Shafiq | 56 | 2026-07-05 | 2026-07-06 |
| Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases EVER001 - Minimal Change Disease (MCD), IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Everest Medicines (China) Co.,Ltd. | 45 | 2026-05-20 | 2026-08-05 |
| Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome Obinutuzumab - Nephrotic Syndrome，Idiopathic | Phase 2 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 10 | 2026-02-01 | 2026-01-26 |
| Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study Conventional 24-week glucocorticoid regimen, short-term course (12 week) glucocorticoid regimen - Idiopathic Nephrotic Syndrome | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 224 | 2026-01-01 | 2025-09-03 |
| Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis ANCA Associated Vasculitis, Extramembranous Glomerulopathy | Recruiting | Assistance Publique - Hôpitaux de Paris | 146 | 2025-11-03 | 2026-06-30 | |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| SLIT ABS: Study on Patients With Autoimmune Podocytopathy Serum and renal tissue analysis - Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome | Not applicable | Recruiting | Meyer Children's Hospital IRCCS | 50 | 2025-06-10 | 2026-04-08 |
| Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes Idiopathic Nephrotic Syndrome (INS) | Recruiting | Assistance Publique - Hôpitaux de Paris | 265 | 2025-04-15 | 2025-08-14 | |
| Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant | Not yet recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 350 | 2025-02-15 | 2025-01-30 | |
| A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease frexalimab, brivekimig, rilzabrutinib - Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | Phase 2 | Recruiting | Sanofi | 84 | 2024-12-19 | 2026-10-19 |
| REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) Prednisone - Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change | Phase 3 | Active not recruiting | The Hospital for Sick Children | 50 | 2024-11-01 | 2026-05-11 |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases WAL0921, Placebo - Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Walden Biosciences | 96 | 2024-07-02 | 2026-08-03 |
| Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Unknown | Assistance Publique - Hôpitaux de Paris | 124 | 2024-06-30 | 2024-06-05 | |
| Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab - Minimal Change Disease | Phase 3 | Not yet recruiting | Air Force Military Medical University, China | 81 | 2024-05-01 | 2024-05-08 |
| Circulating Factors in Nephrotic Syndrome Observation - Nephrotic Syndrome, Membranous Nephropathy | Not yet recruiting | Iain Bressendorff | 104 | 2024-04-01 | 2024-03-19 | |
| Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). - Nephrotic Syndrome | Recruiting | Mario Negri Institute for Pharmacological Research | 100 | 2024-03-19 | 2025-09-04 | |
| Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome Rituximab (genetical recombination), Placebo - Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic | Phase 3 | Active not recruiting | Shoichi Maruyama MD PhD | 88 | 2023-06-24 | 2026-08-12 |
Showing 20 of 75. Sign in to see all of them.
Glomerulosclerosis, Focal Segmental (42) · Nephrotic Syndrome (29) · Glomerulonephritis, Membranous (15) · Kidney Diseases (14) · Glomerulonephritis, IGA (12) · Proteinuria (10) · Diabetic Nephropathies (9) · Macular dystrophy, corneal type 1 (9) · Glomerulonephritis (5) · Renal Insufficiency, Chronic (5) · Nephritis, Hereditary (3) · Disease (2) · Glomerulonephritis, Membranoproliferative (2) · Hematuria, Benign Familial (2)
Female Urogenital Diseases (75) · Female Urogenital Diseases and Pregnancy Complications (75) · Male Urogenital Diseases (75) · Urogenital Diseases (75) · Urologic Diseases (74) · Nephrosis (73) · Kidney Diseases (61) · Nephritis (47) · Glomerulonephritis (43) · Immune System Diseases (20) · Autoimmune Diseases (19) · Pathological Conditions, Signs and Symptoms (19) · Pathologic Processes (12) · Signs and Symptoms (12) · Urination Disorders (11)
Prednisone (7) · Prednisolone (6) · Rituximab (6) · Adrenal Cortex Hormones (3) · Mycophenolic Acid (3) · Tacrolimus (3) · obinutuzumab (2) · ADX-629 (1) · Abatacept (1) · Adalimumab (1) · Cholecalciferol (1) · Congresses as Topic (1) · Control Groups (1) · Cyclophosphamide (1) · Data Collection (1)
Assistance Publique - Hôpitaux de Paris (10) · University of Michigan (5) · Northwell Health (3) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (2) · Goldfinch Bio, Inc. (2) · Mario Negri Institute for Pharmacological Research (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Seoul National University Hospital (2) · The Hospital for Sick Children (2) · University Hospital, Limoges (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Air Force Military Medical University, China (1) · Aldeyra Therapeutics, Inc. (1) · Alexion Pharmaceuticals, Inc. (1) · Astellas Pharma Korea, Inc. (1)
United States (24) · France (15) · China (8) · Italy (7) · Canada (5) · Germany (5) · South Korea (5) · United Kingdom (5) · Australia (3) · Greece (3) · Netherlands (3) · Spain (3) · Belgium (2) · Mexico (2) · Poland (2)
Matthias Kretzler, MD (2) · Amit Dagan, Dr. (1) · Chia-shi Wang, MD, MS (1) · Christina Liakou, MD (1) · Christine Sethna, MD (1) · Dong Ki Kim, MD, PhD (1) · Eloise Salmon, M.D. (1) · Eloise Salmon, MD (1) · Evangelia Dounousi, Medical Degree (1) · Gerald B Appel, MD (1)
PMID 35230699, PMID 38724717, PMID 39513526, PMID 35224732, PMID 12387184, PMID 12478360, PMID 12584259, PMID 12761235, PMID 12763891, PMID 12814058, PMID 15734130, PMID 15882260, PMID 16228184, PMID 16267158, PMID 16935903, PMID 17554565, PMID 17636340, PMID 17681166, PMID 17855645, PMID 22156539, PMID 22722778, PMID 24009220, PMID 25628366, PMID 26577187, PMID 26589142, PMID 26998310, PMID 27445165, PMID 28213606, PMID 30302374, PMID 30385039, PMID 30732999, PMID 30976899, PMID 31769845, PMID 32272901, PMID 32842999, PMID 33611671, PMID 34060483, PMID 34247632, PMID 34796395, PMID 35078538, PMID 37117201, PMID 39431468, PMID 39661388, PMID 39710174, PMID 39808779, PMID 39899371, PMID 40032676, PMID 40337980, PMID 40938675, PMID 41091558
2018 (2), 2025 (2), R01DK131091 (2), R01DK141114 (2), U54DK083912 (2), 2009 (1), 2015 (1), 5RC2DK122397 (1), K23DK093556 (1), K23DK118189 (1)